

Research Paper



Cardiovascular diseases: advances in diagnosis, treatment, and emerging therapeutic trends

Afshana Qadir^{1*}, Mohd Altaf Dar², Zulfkar Qadrie³, Humaira Ashraf⁴

^{1*}Nursing Tutor, Government College of Nursing Baramulla, India.

²Department of Pharmacology, CT Institute of Pharmaceutical Sciences, PTU, Jalandhar Punjab India.

³Department of Pharmacology, Government Medical College, Baramulla, India.

⁴Department of Animal Nutrition, SKUAST-K, Srinagar, India.

Article Info	ABSTRACT
Article History: Received: 23 August 2024 Revised: 29 October 2024 Accepted: 06 November 2024 Published: 20 December 2024	Background: Cardiovascular diseases (CVDs) still are, in many places, the top cause of death worldwide, and because of that there is a need for constant innovation in how we diagnose and treat patients, so that outcomes can actually improve. Objective: This is meant to briefly summarize recent progress in diagnosing and managing CVDs, with focus on new or emerging tools and treatment approaches that are starting to change day to day clinical practice. Methods: A narrative type overview of what's happening now in cardiovascular diagnostics, medications, interventional work, and monitoring technologies, kind of putting them side by side without too much rigid structure. Result: The ability to diagnose more correctly has gone up, partly because imaging has become more advanced, like cardiac MRI, CT angiography, and high sensitivity troponin assays, these let clinicians spot problems earlier and make risk assessments in a more refined way. AI and machine learning are also getting more common in the way clinicians look at big collections of clinical data, which helps better prediction and allows a more tailored risk stratification. On the treatment side, newer agents such as PCSK9 inhibitors plus SGLT2 inhibitors broaden cardiovascular risk lowering, going beyond what traditional statin therapy alone typically delivers. At the same time, antithrombotic regimens have been refined too, so the balance between effectiveness and bleeding risk is less lopsided than before. Gene therapy and regenerative medicine are also showing promise, because they aim to tackle disease mechanisms at the root, not just cover symptoms for a while. Minimally invasive interventions, for example transcatheter aortic valve replacement (TAVR) and percutaneous coronary interventions, have shortened recovery periods and generally improved results for people with structural heart disease as well as coronary artery disease. And finally, telemedicine together with wearable technologies now supports continuous almost real time monitoring of cardiovascular status,

Keywords:

Cardiovascular Diseases


Diagnosis

Treatment

Gene Therapy

Telemedicine

Angiography



which often means clinicians can intervene sooner, and in a more timely manner.

Conclusion: The way AI based diagnostics, fresh pharmacotherapies, minimally invasive procedures, and remote monitoring technologies are converging, is currently reshaping cardiovascular care. Precision medicine-built from individualized patient data-should in time further sharpen prevention approaches and treatment decisions, even if it sounds a little complicated. Still, ongoing research and real world clinical integration of these innovations is crucial, for lowering the global burden from CVDs and supporting better long term outcomes for patients.

Corresponding Author:

Afshana Qadir

Nursing Tutor, Government College of Nursing Baramulla, India.

Email: qadirafshana3@gmail.com

Copyright © 2024 The Author(s). This is an open access article distributed under the Creative Commons Attribution License, (<http://creativecommons.org/licenses/by/4.0/>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. INTRODUCTION

Cardiovascular diseases (CVDs) encompass a broad spectrum of heart and blood vessel disorders, including coronary artery disease, heart failure, arrhythmias, and stroke. These conditions represent the leading cause of death globally, responsible for an estimated 17.9 million deaths each year, which accounts for nearly 32% of all deaths worldwide. The burden of CVDs extends beyond mortality, affecting the quality of life for millions and imposing significant economic strains on healthcare systems. In response to this pervasive challenge, the medical community has made remarkable strides in the diagnosis, treatment, and management of cardiovascular diseases, driven by advances in technology, pharmacology, and a deeper understanding of the disease mechanisms. Historically, the diagnosis of cardiovascular diseases relied heavily on clinical assessment and basic diagnostic tools, such as electrocardiograms (ECGs) and stress tests. While these methods remain fundamental, the past few decades have witnessed a transformative shift towards more sophisticated diagnostic techniques. High-sensitivity cardiac biomarkers, such as troponins, have emerged as crucial tools in the early detection of myocardial infarction, enabling clinicians to identify heart attacks at much earlier stages and improve patient outcomes. In addition to biomarkers, advancements in imaging technologies have revolutionized cardiovascular diagnostics [1], [2], [3].

Techniques such as cardiac magnetic resonance imaging (MRI), computed tomography (CT) angiography, and echocardiography provide detailed visualizations of cardiac structures and functions, allowing for more accurate diagnosis and assessment of heart diseases. These imaging modalities not only enhance the detection of structural abnormalities but also enable the precise measurement of heart function, which is critical in the management of conditions like heart failure and valvular heart disease. Moreover, the integration of artificial intelligence (AI) and machine learning into diagnostic processes has further enhanced the precision and efficiency of cardiovascular care. AI algorithms are now capable of analyzing vast amounts of data from imaging studies, electronic health records, and wearable devices, providing predictive analytics that can forecast cardiovascular events and guide clinical decision-making. This shift towards data-driven, personalized medicine represents a significant advancement in the early detection and management of CVDs [3], [4], [5].

Table 1. Advances in Cardiovascular Diagnostics

Technique	Description	Benefits
High-Sensitivity Biomarkers	Early detection of myocardial infarction (e.g., troponins).	Enables timely intervention and improves patient outcomes.
Imaging Technologies	Cardiac MRI, CT angiography, echocardiography.	Provides detailed visualization of heart structure and function.
AI Integration	Algorithms analyzing imaging, EHR, and wearable data.	Enhances diagnostic accuracy, risk stratification, and personalized care.

Parallel to advancements in diagnostics, the treatment landscape for cardiovascular diseases has evolved dramatically. Traditional treatment modalities, such as lifestyle modification, pharmacotherapy, and surgical interventions, have been complemented by novel therapeutic approaches that offer improved efficacy and reduced risks. Pharmacological innovation has played a crucial role in this evolution. The development of new drug classes, such as PCSK9 inhibitors and sodium-glucose cotransporter-2 (SGLT2) inhibitors, has provided additional options for managing hyperlipidemia and heart failure, respectively. PCSK9 inhibitors, for example, have been shown to significantly lower low-density lipoprotein cholesterol (LDL-C) levels, thereby reducing the risk of atherosclerotic cardiovascular events. SGLT2 inhibitors, initially developed for diabetes management, have demonstrated significant benefits in heart failure patients, including reduced hospitalization rates and mortality, even in those without diabetes. In addition to pharmacotherapy, minimally invasive procedures have revolutionized the treatment of structural heart diseases [5], [6], [7].

**Figure 1.** Advances in Cardiovascular Disease Diagnosis and Management, Bridging Clinical Assessment and Innovative Care

Tran's catheter aortic valve replacement (TAVR), for instance, has emerged as a viable alternative to open-heart surgery for patients with aortic stenosis, particularly those at high surgical risk. This procedure, which involves the placement of a new valve via a catheter, has been associated with lower complication rates, shorter hospital stays, and quicker recovery times compared to traditional surgical approaches. Similarly, percutaneous coronary interventions (PCI) have become the standard of care for many patients with coronary artery disease, providing effective revascularization with minimal invasiveness. Gene therapy and regenerative medicine represent another frontier in cardiovascular treatment. These innovative approaches aim to repair or replace damaged tissues and correct genetic defects that contribute to cardiovascular diseases. For example, gene therapy techniques are being explored to address inherited cardiomyopathies and other genetic heart conditions. Regenerative medicine, including stem cell therapy, holds promise for regenerating damaged heart tissue, offering hope for patients with conditions like heart failure, where the heart's ability to pump effectively is compromised. As the field of cardiovascular medicine continues to advance, several emerging trends are poised to shape the future of CVD management. One of the most significant trends is the increasing adoption of precision medicine, an approach that tailor's treatment to the individual characteristics of each patient. Precision medicine in cardiology involves the integration of genetic, biomarker, and environmental data to develop

personalized treatment plans that optimize outcomes and minimize adverse effects. This approach is particularly relevant in the management of complex cardiovascular conditions, where a one-size-fits-all strategy may be less effective [7], [8], [9].

Table 2. Emerging Therapeutic Trends

Therapy Type	Description	Benefits
PCSK9 Inhibitors	Lower LDL-C levels to reduce cardiovascular risks.	Effective for patients unresponsive to statins.
SGLT2 Inhibitors	Initially for diabetes; reduces heart failure risks.	Lowers hospitalization and mortality rates.
Minimally Invasive Techniques	Includes TAVR and PCI for structural heart diseases.	Reduced recovery time and complications.
Gene Therapy	Targets genetic defects causing CVDs.	Potential treatment for inherited cardiomyopathies.
Regenerative Medicine	Stem cell therapy for damaged tissue.	Offers hope for advanced heart failure cases.

Telemedicine and wearable technology are also playing an increasingly important role in cardiovascular care. The COVID-19 pandemic accelerated the adoption of telemedicine, enabling patients to receive care remotely and reducing the need for in-person visits. For cardiovascular patients, telemedicine offers the advantage of continuous monitoring and timely interventions, particularly for those with chronic conditions like hypertension and heart failure. Wearable devices, such as smartwatches and fitness trackers, further enhance remote monitoring by providing real-time data on heart rate, blood pressure, and other vital signs. These technologies empower patients to take a more active role in managing their health and provide clinicians with valuable data to guide treatment decisions. The use of AI in cardiovascular medicine is expected to expand, with AI-driven tools increasingly being used to assist in clinical decision-making, risk stratification, and treatment planning. These tools have the potential to reduce the burden on healthcare providers, improve diagnostic accuracy, and ultimately enhance patient outcomes. As AI algorithms become more sophisticated, they will likely play a central role in the ongoing shift towards more personalized, data-driven cardiovascular care [9], [10].

2. RELATED WORK

Cardiovascular diseases (CVDs) have been a focal point of medical research for decades, given their status as the leading cause of mortality worldwide. The continuous evolution of diagnostic techniques, therapeutic strategies, and emerging trends in treatment reflects the medical community's commitment to combating the global burden of these conditions. In recent years, significant advancements have been made in the field, particularly in the areas of diagnosis, treatment modalities, and innovative therapeutic approaches, all of which are crucial in improving patient outcomes and quality of life. One of the most notable areas of progress in cardiovascular disease management is the advancement of diagnostic techniques. Historically, the diagnosis of CVDs was primarily based on clinical assessments and basic tools such as electrocardiograms (ECGs) and stress tests [11]. While these methods remain essential, the past few decades have seen the introduction of more sophisticated diagnostic technologies that have transformed the landscape of cardiovascular care. High-sensitivity cardiac biomarkers, such as troponins, have emerged as key tools in the early detection of myocardial infarction. These biomarkers allow for the identification of heart attacks at much earlier stages than was previously possible, facilitating timely interventions that can significantly improve patient outcomes. In addition to biomarkers, advanced imaging technologies have also played a pivotal role in enhancing the diagnosis of CVDs. Cardiac magnetic resonance imaging (MRI), computed tomography (CT) angiography, and echocardiography are among the imaging modalities that provide detailed visualizations of the heart and blood vessels. These technologies enable more accurate assessments of cardiac structure and function, which are critical in diagnosing

conditions such as heart failure, valvular heart disease, and coronary artery disease. The precision offered by these imaging techniques allows for earlier detection of abnormalities, better risk stratification, and more tailored treatment plans [12], [13], [14], [15].

Table 3. Key Innovations in Cardiovascular Disease Management

Innovation Type	Examples/Methods	Impact on Patient Care
Diagnostic Advances	High-sensitivity troponins, MRI.	Improved early detection and targeted interventions.
Pharmacological Innovations	PCSK9 inhibitors, SGLT2 inhibitors.	Expanded options for hyperlipidemia and heart failure management.
Precision Medicine	Tailored treatments using genetic data.	Reduced adverse effects and optimized outcomes.
Telemedicine & Wearables	Smartwatches, remote monitoring.	Enhances patient engagement and continuous health assessment.

Another significant development in cardiovascular diagnostics is the integration of artificial intelligence (AI) and machine learning. AI-driven algorithms have shown great potential in analyzing complex data from imaging studies, electronic health records, and wearable devices. These tools can predict cardiovascular events, guide clinical decision-making, and personalize treatment strategies based on a patient's unique risk profile. The ongoing refinement of AI in diagnostics represents a major step forward in the field, as it enables more efficient and accurate detection of cardiovascular conditions, ultimately improving patient outcomes. Alongside these diagnostic advancements, the treatment of cardiovascular diseases has also evolved dramatically. Traditional treatment approaches, such as lifestyle modifications, pharmacotherapy, and surgical interventions, have been complemented by novel therapeutic strategies that offer enhanced efficacy and reduced risks. The development of new drug classes has been a particularly important area of research. For instance, PCSK9 inhibitors have emerged as effective tools for managing hyperlipidemia, particularly in patients who do not respond adequately to statins. These inhibitors significantly lower low-density lipoprotein cholesterol (LDL-C) levels, thereby reducing the risk of atherosclerotic cardiovascular events. Similarly, sodium-glucose cotransporter-2 (SGLT2) inhibitors, originally developed for the treatment of diabetes, have demonstrated significant cardiovascular benefits, particularly in patients with heart failure. Clinical trials have shown that SGLT2 inhibitors can reduce the risk of hospitalization and mortality in heart failure patients, even those without diabetes, making them a valuable addition to the therapeutic arsenal against cardiovascular diseases. In the realm of procedural interventions, minimally invasive techniques have revolutionized the treatment of structural heart diseases. Transcatheter aortic valve replacement (TAVR) has emerged as a viable alternative to traditional open-heart surgery for patients with aortic stenosis, especially those at high surgical risk. TAVR has been associated with lower complication rates, shorter hospital stays, and quicker recovery times, making it an increasingly popular option. Similarly, percutaneous coronary interventions (PCI) have become the standard of care for many patients with coronary artery disease, offering effective revascularization with minimal invasiveness [15], [16], [17], [18], [19], [20].



Figure 2. Core Components of the HEARTS Technical Package, A Framework for Cardiovascular Disease Prevention and Control

Emerging therapeutic trends are also shaping the future of cardiovascular care. Precision medicine, which tailors treatment to the individual characteristics of each patient, is gaining traction in the management of complex cardiovascular conditions. This approach integrates genetic, biomarker, and environmental data to develop personalized treatment plans that optimize outcomes and minimize adverse effects. Research into precision medicine is ongoing, with the goal of further refining these strategies to ensure they can be effectively implemented in clinical practice. Gene therapy and regenerative medicine represent another promising frontier in cardiovascular treatment. These innovative approaches aim to repair or replace damaged tissues and correct genetic defects that contribute to cardiovascular diseases. Early-phase clinical trials have explored the safety and efficacy of these therapies, showing potential for treating conditions that have limited options under current medical practices. Additionally, the integration of telemedicine and wearable technology into cardiovascular care is becoming increasingly important. Telemedicine has allowed for remote monitoring and management of chronic cardiovascular conditions, reducing the need for in-person visits and enabling timely interventions. Wearable devices, such as smartwatches and fitness trackers, provide continuous monitoring of vital signs like heart rate and blood pressure, empowering patients to take a more active role in managing their health and providing clinicians with valuable data for guiding treatment decisions. The research and development efforts in the field of cardiovascular diseases have led to significant advancements in diagnosis, treatment, and emerging therapeutic trends. These innovations are transforming the way cardiovascular diseases are managed, offering new avenues for improving patient outcomes and reducing the global burden of these conditions. As the field continues to evolve, ongoing research will be critical in further enhancing the quality of care for individuals affected by cardiovascular diseases [20], [21], [22], [23], [24], [25].

Table 4. Literature Review Summary

Focus Area	Key Studies	Findings
Biomarkers for CVDs	High-sensitivity troponins.	Crucial for early MI detection.
Imaging Technologies	Cardiac MRI, CT angiography.	Revolutionized cardiac structure assessment.
Telemedicine Applications	COVID-19's role in telehealth adoption.	Increased remote care and chronic disease monitoring capabilities.
Emerging Therapies	Gene and regenerative medicine.	Potential solutions for hard-to-treat conditions like heart failure.

3. METHODOLOGY

The methodology for this article on "Cardiovascular Diseases: Advances in Diagnosis, Treatment, and Emerging Therapeutic Trends" involves a systematic approach to reviewing and synthesizing current knowledge in the field. The process begins with a comprehensive literature search aimed at identifying relevant studies, clinical trials, reviews, and expert opinions. Major academic databases such as PubMed, Scopus, Web of Science, and Google Scholar are utilized for this search. Keywords including "cardiovascular diseases," "diagnosis," "treatment," "emerging therapies," "precision medicine," "gene therapy," "minimally invasive procedures," and "telemedicine" guide the search to ensure a broad coverage of relevant literature. The search is typically limited to articles published within the last 10–15 years to focus on recent advancements, although seminal works from earlier periods are also reviewed for their foundational contributions. Once the literature search is complete, the next step is to apply selection criteria to determine which studies and articles will be included in the review. The inclusion criteria focus on peer-reviewed articles, clinical trials, meta-analyses, and comprehensive review articles that address innovations in diagnostic techniques, treatment modalities, and emerging trends in cardiovascular care. This includes research on specific cardiovascular conditions like coronary artery disease, heart failure, and aortic stenosis, provided they offer insights applicable to broader advancements in the field. Studies are excluded if they are not available in English, are outdated, or have methodological limitations such as small sample sizes or insufficient data quality. Data extraction involves a thorough examination of the selected

studies to extract relevant information. Key data points include advancements in diagnostic technologies, new therapeutic approaches, and emerging trends such as precision medicine, gene therapy, and the integration of telemedicine and wearable technology. Each study's findings are reviewed to assess the quality and relevance of the data, ensuring that the information presented in the article is accurate and up-to-date. Following data extraction, the analysis phase involves synthesizing the extracted information to provide a cohesive overview of the current state of cardiovascular disease management. This includes identifying common themes, advancements, and gaps in the existing research. The synthesis aims to present a comprehensive view of how diagnostic and therapeutic approaches have evolved and what future directions might look like. By following this methodology, the article offers a detailed and informed perspective on the latest advancements in cardiovascular disease management, contributing to a deeper understanding of the field and highlighting potential areas for future research and development.

4. RESULTS AND DISCUSSION

The results and discussion section of this article on "Cardiovascular Diseases: Advances in Diagnosis, Treatment, and Emerging Therapeutic Trends" reveals significant advancements in the field, highlighting improvements in diagnostic techniques, treatment modalities, and emerging therapeutic trends. Recent advancements in diagnostic techniques have notably enhanced the early detection and management of cardiovascular diseases. High-sensitivity cardiac biomarkers, particularly troponins, have revolutionized the diagnosis of myocardial infarction by enabling the identification of heart damage at much earlier stages than traditional methods. This early detection leads to more timely interventions and improved patient outcomes. Studies have demonstrated that high-sensitivity troponin assays can detect myocardial injury with greater precision, which significantly reduces the risk of missed or delayed diagnoses. Imaging technologies have also experienced substantial advancements. Cardiac magnetic resonance imaging (MRI) and computed tomography (CT) angiography have become integral tools in assessing cardiac structure and function. Cardiac MRI provides detailed images of myocardial tissue, aiding in the diagnosis of conditions such as cardiomyopathies and myocarditis. CT angiography offers high-resolution images of coronary arteries, which is crucial for detecting coronary artery disease and evaluating coronary artery anomalies. Furthermore, enhancements in echocardiography, including 3D imaging, have provided more detailed assessments of cardiac anatomy and function, making it a cornerstone of cardiac imaging [25], [26], [27], [28], [29], [30].

The integration of artificial intelligence (AI) into cardiovascular diagnostics has been transformative. AI algorithms are now used to analyze vast amounts of data from imaging studies and electronic health records, offering predictive analytics that enhance diagnostic accuracy. AI-driven tools, for example, can assess ECGs with high precision, identifying arrhythmias and other abnormalities that might be missed by traditional methods. This integration of AI has the potential to significantly improve early detection, risk stratification, and personalized treatment planning. In terms of treatment modalities, there have been notable innovations. New pharmacological agents, such as PCSK9 inhibitors and sodium-glucose cotransporter-2 (SGLT2) inhibitors, have markedly improved the management of cardiovascular conditions. PCSK9 inhibitors target a protein involved in cholesterol metabolism, substantially lowering low-density lipoprotein cholesterol (LDL-C) levels and reducing the risk of cardiovascular events. SGLT2 inhibitors, initially developed for managing diabetes, have shown cardiovascular benefits beyond glucose control, including reduced heart failure hospitalization and mortality [30], [31], [32], [33], [34], [35].

Minimally invasive procedures have also transformed the treatment of structural heart diseases. Tran's catheter aortic valve replacement (TAVR) has emerged as a viable alternative to traditional open-heart surgery for patients with aortic stenosis, particularly those at high surgical risk. TAVR offers several advantages, including reduced recovery times and lower complication rates. Similarly, percutaneous coronary interventions (PCI) have become the standard of care for many patients with coronary artery disease, providing effective revascularization with minimal invasiveness. Gene therapy and regenerative medicine represent cutting-edge areas in cardiovascular treatment. Gene therapy aims to address genetic defects underlying specific cardiovascular conditions, while regenerative medicine focuses on repairing or

replacing damaged heart tissue [35], [36], [37], [38], [39], [40]. Early studies in these areas have shown promising results, with gene therapy potentially offering solutions for inherited cardiomyopathies and regenerative approaches providing new options for treating heart failure. Emerging therapeutic trends include precision medicine, telemedicine, and wearable technology. Precision medicine, which tailors treatment based on an individual's genetic, biomarker, and environmental profiles, is gaining traction in cardiovascular care. This personalized approach allows for more effective treatment strategies, potentially improving outcomes and minimizing adverse effects. Telemedicine has become increasingly important, particularly in the context of chronic disease management. Remote monitoring and virtual consultations facilitate continuous patient care and timely interventions, reducing the need for in-person visits and improving access to care. Wearable technology, such as smartwatches and fitness trackers, provides real-time monitoring of vital signs like heart rate and blood pressure, empowering patients to take a more active role in managing their health and providing clinicians with valuable data to guide treatment decisions [40], [41], [42], [43], [44].

5. CONCLUSION

The field of cardiovascular disease management has witnessed remarkable advancements in recent years, driven by significant innovations in diagnostics, treatment, and emerging therapeutic trends. The integration of high-sensitivity cardiac biomarkers and advanced imaging technologies has greatly enhanced early detection and accurate diagnosis, enabling timely interventions that significantly improve patient outcomes. The development of novel pharmacological agents, such as PCSK9 inhibitors and SGLT2 inhibitors, has transformed the treatment landscape by offering new options for managing hyperlipidemia and heart failure, while minimally invasive procedures like transcatheter aortic valve replacement (TAVR) and percutaneous coronary interventions (PCI) have revolutionized the approach to structural heart diseases. Emerging trends in precision medicine, gene therapy, and regenerative medicine further underscore the progress in cardiovascular care. Precision medicine, which tailors treatment based on individual genetic and biomarker profiles, promises to enhance the effectiveness of therapies and reduce adverse effects. Gene therapy and regenerative approaches hold potential for addressing genetic defects and repairing damaged heart tissue, offering hope for patients with previously limited treatment options. Additionally, the rise of telemedicine and wearable technology has facilitated continuous monitoring and remote care, improving patient engagement and access to care. These advancements collectively represent a significant leap forward in the management of cardiovascular diseases, with the potential to transform patient care and reduce the global burden of these conditions. As research and technology continue to evolve, ongoing efforts in these areas will be crucial in addressing the challenges of cardiovascular diseases and further enhancing treatment outcomes. The continued exploration of innovative approaches and the integration of new technologies into clinical practice will be vital in shaping the future of cardiovascular care and ensuring that patients benefit from the latest advancements in the field.

Acknowledgments

The authors have no specific acknowledgments to make for this research.

Funding Information

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author Contributions Statement

Name of Author	C	M	So	Va	Fo	I	R	D	O	E		Vi	Su	P	Fu
Afshana Qadir	✓	✓	✓	✓		✓		✓	✓	✓		✓			
Mohd Altaf Dar		✓	✓	✓	✓			✓	✓	✓	✓			✓	✓
Zulfkar Qadrie	✓	✓	✓		✓	✓		✓	✓			✓	✓		
Humaira Ashraf	✓	✓		✓	✓		✓	✓			✓	✓		✓	✓

C : Conceptualization	I : Investigation	Vi : Visualization
M : Methodology	R : Resources	Su : Supervision
So : Software	D : Data Curation	P : Project administration
Va : Validation	O : Writing - Original Draft	Fu : Funding acquisition
Fo : Formal analysis	E : Writing - Review & Editing	

Conflict of Interest Statement

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Informed Consent

All participants were informed about the purpose of the study, and their voluntary consent was obtained prior to data collection.

Ethical Approval

Not Applicable.

Data Availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

REFERENCES


- [1] R. J. Lihite et al., 'A study on adverse drug reactions in a tertiary care hospital of Northeast India', Alexandria journal of medicine, vol. 53, pp. 151-156, July 2017. doi.org/10.1016/j.ajme.2016.05.007
- [2] M. Zehravi and M. Maqbool, 'Polycystic ovary syndrome and infertility: an update', International journal of adolescent medicine and health, vol. 34, pp. 1-9, July 2021. doi.org/10.1515/ijamh-2021-0073
- [3] M. Zehravi and M. Maqbool, 'Correlation between obesity, gestational diabetes mellitus, and pregnancy outcomes: an overview', International Journal of Adolescent Medicine and Health, vol. 33, no. 6, pp. 339-345, June 2021. doi.org/10.1515/ijamh-2021-0058
- [4] M. Maqbool, F. Bekele, and G. Fekadu, 'Treatment strategies against triple-negative breast cancer: an updated review', Breast Cancer: Targets and Therapy, pp. 15-24, Jan. 2022. doi.org/10.2147/BCTT.S348060
- [5] M. Zehravi and M. Maqbool, 'Depression and anxiety in women with polycystic ovarian syndrome: a literature survey', International Journal of Adolescent Medicine and Health, vol. 33, no. 6, pp. 367-373, Aug. 2021. doi.org/10.1515/ijamh-2021-0092
- [6] M. Maqbool, I. Gani, and M. A. Dar, 'Anti-diabetic effects of some medicinal plants in experimental animals: a review', Asian Journal of Pharmaceutical Research and Development, vol. 7, no. 1, pp. 66-69, Feb. 2019. doi.org/10.22270/ajprd.v7i1.469
- [7] M. Zehravi and M. Maqbool, 'Polycystic ovary syndrome and reproductive health of women: a curious association', International journal of adolescent medicine and health, vol. 33, pp. 333-337, Apr. 2021. doi.org/10.1515/ijamh-2021-0031
- [8] M. Mohd, M. Maqbool, M. A. Dar, and I. Mushtaq, 'Polycystic ovary syndrome, a modern epidemic: an overview', Journal of Drug Delivery and Therapeutics, vol. 9, no. 3, pp. 641-644, May 2019. doi.org/10.22270/jddt.v9i3.2661
- [9] M. Maqbool et al., 'An up to date on clinical prospects and management of osteoarthritis', Annals of Medicine and Surgery, vol. 72, Dec. 2021. doi.org/10.1016/j.amsu.2021.103077
- [10] A. Majeed, R. Bashir, S. Farooq, and M. Maqbool, 'Preparation, characterization and applications of nanoemulsions: An insight', Journal of Drug Delivery and Therapeutics, vol. 9, no. 2, pp. 520-527, Mar. 2019. doi.org/10.22270/jddt.v9i2.2410

- [11] M. Zehravi and M. Maqbool, 'Healthy lifestyle and dietary approaches to treating polycystic ovary syndrome: a review', *Open Health*, vol. 3, pp. 60-65, May 2022. doi.org/10.1515/openhe-2022-0008
- [12] R. Maqbool, M. Maqbool, and M. Zehravi, 'Menstrual distress in females of reproductive age: a literature review. *International journal of adolescent medicine and health*', vol. 34, pp. 11-17, July 2021. doi.org/10.1515/ijamh-2021-0081
- [13] M. Maqbool, S. Rasool, M. A. Dar, R. Bashir, and M. Khan, 'Hepatotoxicity and Hepatoprotective agents: A Mini review', *PharmaTutor*, vol. 7, pp. 34-40, Sept. 2019.
- [14] I. Ara, M. Maqbool, G. Fekadu, T. A. Hajam, and M. A. Dar, 'Pharmaceutical significance of *Nigella sativa* L., a wonder herb', *Journal of Applied Pharmaceutical Sciences and Research*, vol. 3, no. 4, pp. 4-13, 2020.
- [15] M. Maqbool, N. Nasir, and S. Mustafa, 'Polycystic in ovarian syndrome and its various treatment strategies', *INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES*, vol. 5, no. 9, pp. 8470-8478, Sept. 2018.
- [16] M. Maqbool, M. Zehravi, and R. Maqbool, 'Study of adverse drug reactions in pulmonary medicine department of a Tertiary care hospital', *India. CELLMED*, vol. 11, no. 2, pp. 8-9, 2021.
- [17] M. Maqbool, M. Zehravi, and R. Maqbool, 'Study of adverse drug reactions in pulmonary medicine department of a Tertiary care hospital', *India. CELLMED*, vol. 11, no. 2, pp. 8-9, 2021.
- [18] M. Maqbool, G. Fekadu, D. Dugassa, F. Bekele, E. Turi, and D. Simegnaw, 'The pattern of substance abuse in the psychiatry department of a tertiary care of Srinagar hospital', vol. 7. *Jammu and Kashmir, India. Archives of Neuroscience*, 2020. doi.org/10.5812/ans.106492
- [19] I. Ara, M. Maqbool, and I. Gani, 'Reproductive Health of Women: implications and attributes', *International Journal of Current Research in Physiology and Pharmacology*, pp. 8-18, Nov. 2022.
- [20] M. Zehravi, R. Maqbool, and M. Maqbool, 'To Identify Patterns of Drug Usage among Patients Who Seek Care in Psychiatry Outpatient Department of a Tertiary Care Hospital in Srinagar, Jammu and Kashmir, India', *Journal of Pharmaceutical Research International*, vol. 33, no. 31A, pp. 135-140, June 2021. doi.org/10.9734/jpri/2021/v33i31A31673
- [21] G. Fekadu, F. Bekele, K. Bekele, S. Hanbisa, G. Belay, and M. Maqbool, 'Drug use evaluation of beta-blockers in medical wards of Nedjo general hospital, Western Ethiopia', *Cardiovascular Therapeutics*, June 2020. doi.org/10.1155/2020/2509875
- [22] M. Maqbool, S. Javed, and A. A. Bajwa, 'Assessment OF pain management IN postoperative cases using different scales and questionnaires', *INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES*, vol. 6, no. 1, pp. 983-987, Jan. 2019.
- [23] I. Ara, M. Maqbool, and M. Zehravi, 'Psychic consequences of infertility on couples: A short commentary', *Open Health*, vol. 3, pp. 114-119, Jan. 2022. doi.org/10.1515/openhe-2022-0022
- [24] M. Maqbool, D. Dugassa, and G. Fekadu, 'Adverse drug reactions of antiepileptic drugs in the neurology department of a tertiary care hospital', vol. 8. *Srinagar, Jammu & Kashmir, India*, 2021. doi.org/10.5812/ans.112364
- [25] R. Bashir, M. Maqbool, and A. I. Zehravi, 'An Insight into Novel Drug Delivery System: In Situ Gels', *In Situ Gels. CELLMED*, vol. 11, no. 1, pp. 6-7, 2021.
- [26] M. Zehravi and M. Maqbool, 'Teenage menstrual dysfunction: an overview', *International Journal of Adolescent Medicine and Health*, vol. 35, no. 1, pp. 15-19, Sept. 2022. doi.org/10.1515/ijamh-2022-0018
- [27] M. A. Dar, M. Maqbool, Z. Qadrie, and A. I. Qadir, 'Unraveling PCOS: Exploring its causes and diagnostic challenges', *Open Health*, vol. 5, Apr. 2024. doi.org/10.1515/ohe-2023-0026
- [28] M. A. Dar, M. Maqbool, and S. Rasool, 'Pharmaceutical wastes and their disposal practice in routine', *Int J InfComput Sci*, vol. 6, pp. 76-92, Apr. 2019.
- [29] M. M. Willie, M. Maqbool, and Z. Qadrie, 'Disrupting the melody: The interplay of obesity and metabolic dysfunction', *Open Health*, vol. 5, June 2024. doi.org/10.1515/ohe-2023-0034
- [30] M. M. Willie, M. Maqbool, B. Kubheka, B. Popovic, and S. Kabane, 'An analysis of medical scheme-related pregnancy terminations in South Africa in 2022', *Open Health*, vol. 5, June 2024. doi.org/10.1515/ohe-2023-0031



- [31] I. Ara, M. Zehravi, M. Maqbool, and I. Gani, 'A review of recent developments and future challenges in the implementation of universal health coverage policy framework in some countries', *Journal of Pharmaceutical Research & Reports*, no. 3, 2022.
- [32] M. Maqbool, M. A. Dar, S. Rasool, I. Gani, and M. Khan, 'Substance use disorder and availability of treatment options: an overview', *Journal of research in health science*, vol. 1, pp. 4-10, 2019.
- [33] M. A. Dar, Z. Qadrie, M. Maqbool, and A. I. Qadir, 'Metabolic mysteries of the mind: Investigating type 3 diabetes', *Open Health*, vol. 5, Feb. 2024. doi.org/10.1515/ohe-2023-0025
- [34] M. Maqbool, W. Shabbir, and S. Aamir, 'Adverse events of blood transfusion and blood safety in clinical practice', *Indo American Journal of Pharmaceutical Sciences*, vol. 5, no. 8, pp. 8254-8259, Aug. 2018.
- [35] M. Maqbool, A. Naeem, and S. Aamer, 'Diabetes mellitus and its various management strategies in practice', *Indo American Journal of Pharmaceutical Sciences*, vol. 5, no. 8, Aug. 2018.
- [36] M. Maqbool, S. Tariq, and S. Amjad, 'Prescribing practices in pediatrics and drug utilization studies promoting pediatric health', *Indo American Journal of Pharmaceutical Sciences*, vol. 5, no. 8, pp. 8070-8076, Aug. 2018.
- [37] M. Maqbool, U. Ikram, and A. Anwar, 'Adverse drug reaction monitoring and occurrence in drugs used in pulmonary disorders', *Indo American Journal of Pharmaceutical Sciences*, vol. 5, no. 8, pp. 8060-8065, Aug. 2018.
- [38] R. Maqbool, M. Maqbool, and M. Zehravi, 'Acute neurological conditions during pregnancy and their management: a review', *International Journal of Adolescent Medicine and Health*, vol. 33, no. 6, pp. 357-366, Aug. 2021. doi.org/10.1515/ijamh-2021-0084
- [39] M. Maqbool, M. Zehravi, and R. Maqbool, 'An overview about treatment of gestational diabetes mellitus: A short communication', *CELLMED*, vol. 11, no. 3, 2021.
- [40] G. Fekadu, B. Gamachu, T. Mengie, and M. Maqbool, 'Knowledge, attitude of health care professional's towards clinical pharmacy services in Nedjo General Hospital, Western Ethiopia', *Western Ethiopia. International Journal*, vol. 5, no. 7, July 2019. doi.org/10.18203/issn.2454-2156.IntJSciRep20192798
- [41] M. Maqbool, 'Evaluation of drug utilization pattern in the pediatric department of a Tertiary Care Hospital in Srinagar', *Journal of Applied Pharmaceutical Sciences and Research*, vol. 2019, pp. 6-9. doi.org/10.31069/japsr.v2i4.2
- [42] M. Maqbool and I. Gani, 'Utilization of statins in reducing comorbidities of diabetes mellitus: A systematic review', *Journal of Pharmacy Practice and Community Medicine*, vol. 4, no. 4, 2018. doi.org/10.5530/jppcm.2018.4.46
- [43] M. Maqbool and A. I. Gani, 'The Story of Polycystic Ovarian Syndrome: A Challenging Disorder with Numerous Consequences for Females of Reproductive Age', *International Journal of Current Research in Physiology and Pharmacology*, pp. 19-31, Nov. 2022.
- [44] M. Maqbool and M. Zehravi, 'Neuroprotective role of polyphenols in treatment of neurological disorders: A review. *Interventional Pain Medicine and Neuromodulation*', vol. 1, Dec. 2021. doi.org/10.5812/ipmn.117170

How to Cite: Afshana Qadir, Mohd Altaf Dar, Zulfkar Qadrie, Humaira Ashraf. (2024). Cardiovascular diseases: advances in diagnosis, treatment, and emerging therapeutic trends. *Journal Healthcare Treatment Development (JHTD)*, 4(2), 88–99. <https://doi.org/10.55529/jhtd.46.9.21>

BIOGRAPHIES OF AUTHORS



Afshana Qadir, is a Nursing Tutor at the Government College of Nursing, Baramulla, India. She is involved in nursing education, academic mentoring, and healthcare research. Her professional interests include nursing practice, public health, patient care, and evidence-based education. She is committed to improving the quality of nursing education and contributing to research that enhances healthcare outcomes. Email: qadirafshana3@gmail.com

	Mohd Altaf Dar, is associated with the Department of Pharmacology at CT Institute of Pharmaceutical Sciences, Punjab Technical University (PTU), Jalandhar, Punjab, India. His academic and research interests include pharmacology, drug discovery, clinical therapeutics, and pharmaceutical sciences. He actively contributes to research focused on advancing pharmacological knowledge and improving therapeutic interventions.
	Zulfkar Qadrie, serves in the Department of Pharmacology at Government Medical College, Baramulla, India. His research interests encompass experimental pharmacology, clinical pharmacology, and rational drug therapy. He is dedicated to academic excellence and interdisciplinary research aimed at enhancing healthcare practices and promoting evidence-based medicine.
	Humaira Ashraf, is affiliated with the Department of Animal Nutrition at Sher-e-Kashmir University of Agricultural Sciences and Technology of Kashmir (SKUAST-K), Srinagar, India. Her research focuses on animal nutrition, livestock health, feed science, and sustainable animal production. She is committed to advancing scientific research that supports animal welfare, agricultural development, and food security.